LCM
ORIC icon

Lynwood Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Lynwood Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,000
Closed -$194K – 104
2023
Q2 		$194K Buy
+25,000
New +$142K 0.25% 68

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Lynwood Capital Management's ORIC Position: Q3 2023 in Review

Lynwood Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q3 2023, closing a stake of 25,000 shares — an estimated $194K sold.

Lynwood Capital Management first reported a position in ORIC in Q2 2023 and held it in 1 quarter. The position peaked at $194K in Q2 2023. 90 funds tracked by Wall St. Rank hold ORIC as of Q3 2023.

  • Lynwood Capital Management reported no remaining Oric Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 25,000 Oric Pharmaceuticals shares in Q3 2023, an estimated $194K.
  • Lynwood Capital Management first reported a position in Oric Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Lynwood Capital Management's Oric Pharmaceuticals position peaked at $194K in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2023.

Based on Lynwood Capital Management's 13F filing for Q3 2023, filed 1 Nov 2023.